Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alcuronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 14/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcuronium SCHEMBL1649633 | 0.99 | CHRNA7 (0.98) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Alcuronium SCHEMBL30817419 | 0.99 | CHRNA7 (0.98) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Alcuronium SCHEMBL122972 | 0.99 | CHRNA7 (0.98) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Hydrochloric Acid SCHEMBL31650965 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Bisnordihydrotoxiferine SCHEMBL29525342 | 0.60 | CHRNA7 (0.56) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| Isostrychnine SCHEMBL29898321 | 0.57 | CHRNA7 (0.43) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| SCHEMBL31237286 | 0.54 | GLRA1 (0.39) | CHRNA7CHRM2CHRNA4KCNH2HTR3A | |
| SCHEMBL20495361 | 0.45 | ALDH1A1 (0.43) | — | |
| SCHEMBL4906291 | 0.43 | SIGMAR1 (0.35) | — | |
| Naphthalene SCHEMBL27801470 | 0.43 | TSHR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1024 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716779-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2020-07-21 | — | — | US | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-20190083465-A1 | Methods And Compositions For Treating Foot Or Hand Pain | SANDERS JENNIFER L (US) | 2019-03-21 | — | — | US | claimed |
| US-10195180-B2 | Methods and compositions for treating foot or hand pain | SANDERS JENNIFER L (US) | 2019-02-05 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140371256-A1 | PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT | CHILDREN'S HOSPITAL MEDICAL CENTER | 2014-12-18 | — | — | US | claimed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | claimed |
| EP-2785874-A1 | PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT | Children's Hospital Medical Center (US) | 2014-10-08 | — | — | EP | claimed |
| US-8758816-B2 | Compositions comprising azelastine and methods of use thereof | MEDA PHARMACEUTICALS INC. (US) | 2014-06-24 | — | — | US | claimed |
| WO-2013082308-A1 | PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2013-06-06 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006113462-A2 | FORMULATIONS OF QUATERNARY AMMONIUM NEUROMUSCULAR BLOCKING AGENTS | LYOTROPIC THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20060234989-A1 | Formulations of quaternary ammonium neuromuscular blocking agents | LYOTROPIC THERAPEUTICS, INC. | 2006-10-19 | — | — | US | claimed |
| US-20050008702-A1 | Rupturing controlled release device having a preformed passageway | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2005-01-13 | — | — | US | claimed |
| US-20040204413-A1 | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant | OSMOTICA CORP. (VG) | 2004-10-14 | — | — | US | claimed |
| EP-1362585-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT | Osmotica Corp. (VG) | 2003-11-19 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |